Olutasidenib not checked
Rigel Pharmaceuticals · Forma Therapeutics, Inc. · FT-2102
FollowEvery change as it happens, and a Monday email
Trials
2 active
4 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive repeated dosing of olutasidenib from Day 5 to Day 22 until steady state, with an option to continue treatment up to Day 64”In the company’s words, NCT07486713 on ClinicalTrials.gov
- Tested for
- AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies, High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV and 15 more
- Main trialPhase 4
- “A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.”In the company’s words, NCT07486713 on ClinicalTrials.gov
- Other names
- FT-2102
Other drugs for AML (Acute Myeloid Leukemia)
- Pivekimab SunirineAbbVie · Phase 2/3
- QTX-2101Quetzal Therapeutics · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- QuizartinibDaiichi Sankyo · Phase 3
- MocravimodPriothera SAS · Phase 3
- ATOSDK Therapeutics, Inc. · Phase 3
Coming up2
- 30 Apr 2027Phase 4 trial completes · ClinicalTrials.gov
- Jun 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 30 Apr 2027 | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies | |
| Phase 2Recruiting | Jun 2029 | Study of Olutasidenib and Temozolomide in HGG | |
| Phase 1/2Completed | 24 May 2021 | A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | |
| Phase 1/2Completed | 28 Dec 2023 | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026